Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Biochem J ; 435(1): 207-16, 2011 Apr 01.
Article in English | MEDLINE | ID: mdl-21210766

ABSTRACT

Cellular deposits of oxidized and aggregated proteins are hallmarks of a variety of age-related disorders, but whether such proteins contribute to pathology is not well understood. We previously reported that oxidized proteins form lipofuscin/ceroid-like bodies with a lysosomal-type distribution and up-regulate the transcription and translation of proteolytic lysosomal enzymes in cultured J774 mouse macrophages. Given the recently identified role of lysosomes in the induction of apoptosis, we have extended our studies to explore a role for oxidized proteins in apoptosis. Oxidized proteins were biosynthetically generated in situ by substituting oxidized analogues for parent amino acids. Apoptosis was measured with Annexin-V/PI (propidium iodide), TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling), MMP (mitochondrial membrane permeabilization), caspase activation and cytochrome c release, and related to lysosomal membrane permeabilization. Synthesized proteins containing the tyrosine oxidation product L-DOPA (L-3,4-dihydroxyphenylalanine) were more potent inducers of apoptosis than proteins containing the phenylalanine oxidation product o-tyrosine. Apoptosis was dependent upon incorporation of oxidized residues, as indicated by complete abrogation in cultures incubated with the non-incorporation control D-DOPA (D-3,4-dihydroxyphenylalanine) or when incorporation was competed out by parent amino acids. The findings of the present study suggest that certain oxidized proteins could play an active role in the progression of age-related disorders by contributing to LMP (lysosomal membrane permeabilization)-initiated apoptosis and may have important implications for the long-term use of L-DOPA as a therapeutic agent in Parkinson's disease.


Subject(s)
Apoptosis , Levodopa/adverse effects , Levodopa/metabolism , Monocytes/metabolism , Protein Biosynthesis , Tyrosine/adverse effects , Tyrosine/metabolism , Aging , Annexin A5/metabolism , Caspase 3/metabolism , Cell Line , Ceroid/adverse effects , DNA Fragmentation , Enzyme Activation , Humans , Intracellular Membranes , Lipofuscin/adverse effects , Lysosomes , Membrane Potential, Mitochondrial , Mitochondrial Membranes , Oxidation-Reduction , Permeability
SELECTION OF CITATIONS
SEARCH DETAIL